HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drugstore.com

This article was originally published in The Rose Sheet

Executive Summary

Net sales jumped 38.3% to $34 mil. and net loss decreased from $54.7 mil. to $32.1 mil. in second quarter, e-tailer announces. Firm continues to slash marketing and sales costs, cutting spending 67.5% to $8.3 mil. in Q2; total expenses were down 22.5% to $63.3 mil. Co-marketing deal with Amazon.com is re-negotiated, "reducing minimum cash payments due under the agreement from $30 mil. to $9 mil." and changing termination date to June 25, 2002. Restructuring charges in order of $7.3 mil. incurred as result of forfeiture of cancelled lease deposit for new corporate office space negotiated in March. Marketing and sales expenses related to agreement totaled $4.6 mil. in second quarter, firm notes in 10Q filing. Retailer projects sales of $135 mil.-$145 mil. for year, compared to $110 mil. in fiscal 2000

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel